Equities

23andMe Holding Co.

ME:NAQ

23andMe Holding Co.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.08 / 2.54%
  • Shares traded301.27k
  • 1 Year change-81.29%
  • Beta1.1846
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

  • Revenue in USD (TTM)193.26m
  • Net income in USD-615.31m
  • Incorporated2021
  • Employees560.00
  • Location
    23andMe Holding Co.349 Oyster Point BoulevardSOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 938-6300
  • Fax+1 (302) 636-5454
  • Websitehttps://investors.23andme.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Concord Medical Services Hldgs Ltd (ADR)65.10m-52.30m18.24m727.00------0.2801-11.97-11.9714.90-67.980.074313.395.3589,544.35-10.23-9.49-111.95-39.24-17.13-15.06-137.67-134.560.4556-1.890.6369--13.8423.0039.21---6.88--
ProPhase Labs Inc12.75m-27.76m18.26m113.00--0.3828--1.43-1.50-1.500.68872.000.1393.740.3629112,858.40-30.250.9106-40.111.12-32.3850.32-217.640.93251.33-12.780.2837665.78-63.8127.59-190.90--86.46--
Elite Health Systems Inc0.00-1.18m21.73m2.00--5.94-----0.0938-0.09380.000.21060.00----0.00-45.56-14.62-49.63-19.89-------36.77----0.00------38.97------
Burning Rock Biotech Ltd (ADR)70.36m-78.22m47.60m786.00--0.5081--0.6766-48.55-48.5512.479.130.43311.972.6889,513.99-48.15-37.09-65.09-45.2967.7170.02-111.18-123.882.85--0.00---4.5820.8132.69---17.61--
CRYO-CELL International, Inc.31.84m-8.93m63.45m82.00------1.99-1.08-1.083.86-1.190.47989.354.78388,274.30-13.450.4686-18.450.709973.6670.09-28.040.81330.5699------3.321.41-443.57--60.30--
Exagen Inc55.75m-16.93m73.02m174.00--5.72--1.31-0.9383-0.93833.090.73451.07--4.22320,408.00-32.39-30.21-39.53-33.7558.8054.86-30.36-55.36---6.880.6148--15.3310.1350.01--33.00--
23andMe Holding Co.193.26m-615.31m75.91m560.00--0.7984--0.3928-25.27-25.277.843.950.34516.93198.52345,107.20-109.86---142.15--46.5146.35-318.39-121.631.14--0.00---26.66-13.01-113.92---19.09--
Cardiff Lexington Corp7.22m-2.84m97.74m10.000.7895----13.548.233.610.96050.58380.3436--0.542722,096.00-9.27---25.14--49.3262.01-26.98-----0.00990.4916----39.71--------
American Well Corp254.04m-214.08m120.11m1.10k--0.356--0.4728-14.54-14.5417.2222.020.454526.313.74230,104.20-38.46-28.25-49.63-32.6634.8040.51-84.63-121.272.88--0.00---6.5517.85-149.66--51.49--
Zomedica Corp26.73m-62.19m128.57m144.00--0.6338--4.81-0.0635-0.06350.02730.2070.10931.7714.31185,604.20-25.43-14.03-26.22-14.4569.64---232.70-220.9810.15--0.00--33.05---102.93--89.85--
Data as of Nov 21 2024. Currency figures normalised to 23andMe Holding Co.'s reporting currency: US Dollar USD

Institutional shareholders

13.63%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024772.52k4.41%
Euclidean Capital LLCas of 30 Sep 2024512.16k2.92%
BlackRock Fund Advisorsas of 30 Sep 2024233.76k1.34%
Geode Capital Management LLCas of 30 Sep 2024212.31k1.21%
Renaissance Technologies LLCas of 30 Sep 2024154.44k0.88%
Millennium Management LLCas of 30 Sep 2024137.32k0.78%
GSA Capital Partners LLPas of 30 Sep 2024115.81k0.66%
Wittenberg Investment Management, Inc.as of 30 Sep 2024115.75k0.66%
ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Sep 202475.12k0.43%
SSgA Funds Management, Inc.as of 30 Sep 202458.33k0.33%
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.